Navigation Links
Isis Reports Financial Results and Highlights for Second Quarter of 2008
Date:8/7/2008

ced 2008 mipomersen development plan with Genzyme

-- Reported preclinical study in Circulation showing that mipomersen

lowers Lp(a) and oxidized-LDL, independent risk factors for

cardiovascular disease

-- Initiated Phase 3 study in heterozygous FH subjects with coronary

artery disease

-- Granted broad patent coverage for antisense compounds targeting

apolipoprotein B, U.S. Patent No. 7,407,943 entitled "Antisense

modulation of Apolipoprotein B Expression"

Metabolic Program

-- Highlighted our robust diabetes and obesity portfolio with nine

presentations and posters at the American Diabetes Association meeting

-- Presented new preclinical data relating to ISIS 388626, Isis' drug

targeting SGLT2

-- Presented results from eight research programs on novel targets

that offer new mechanisms to address metabolic diseases, including

obesity

Other Partnered Programs

-- ATL and Teva reported encouraging Phase 2 results for ATL/TV1102,

targeting VLA-4 in patients with multiple sclerosis

-- Partnered oncology drugs highlighted at the American Society of

Clinical Oncology demonstrate the potential of antisense technology to

treat multiple cancers

-- OncoGenex reported encouraging Phase 2 results on OGX-011,

targeting clusterin, in patients with hormone refractory prostate

cancer

-- Eli Lilly and Company reported positive Phase 1 clinical trial

results for LY2181308, targeting survivin

-- Atlantic Healthcare received U.S. orphan drug designation for

alicaforsen for the treatment of pouchitis

-- Altair Therapeutics advanced AIR 645 into Phase 1 studies for the

treatment of asthma

Regulus Therapeutics (microRNA Joint Venture)

-- Entered into strategic alliance wit
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Barr Reports Second Quarter 2008 GAAP Earnings of $0.52 Per Share; Adjusted Earnings of $0.64 Per Share
2. PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
3. Caliper Life Sciences Reports Second Quarter 2008 Results
4. Watson Pharmaceuticals Reports Second Quarter 2008 Results
5. EntreMed Reports Second Quarter 2008 Financial Results
6. Transgenomic Reports Second Quarter 2008 Results
7. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
8. Bionovo Reports Second Quarter 2008 Financial Results
9. AtriCure Reports Record Second Quarter 2008 Financial Results
10. AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008
11. eResearchTechnology Reports Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... (PRWEB) December 23, 2014 Earlier this ... James L. Sherley, director of the Adult Stem Cell ... an often overlooked and under appreciated unique property of ... by Distributed Stem Cells: Misunderstood in the Past, Important ... to congress participants. He gave the address at ...
(Date:12/24/2014)... 23, 2014 According to Ross Selinger, President ... of ITRA Global, the national office market continues to be ... This is evidenced by the third quarter’s surprising 3.9% GDP, ... Low energy costs have held inflation down and the Fed ... the housing market remaining soft. , This solid economic news ...
(Date:12/24/2014)... The report expects global cell isolation and expansion market ... a carefully analyzed data about the vital drivers, restraints, ... Full Copy of Report @ http://bit.ly/1yUxy0T , ... expansion will keep witnessing growth at an impressive CAGR ... driven by rapid technological advancements, government funding and investments, ...
(Date:12/24/2014)... AUSTIN, Texas , Dec. 23, 2014 /PRNewswire/ ... solutions company focused on gynecologic disease, announced today ... W. Schuler , Birchview Fund LLC and several ... million of unregistered shares of Vermillion,s common stock ... common stock in a private placement.  ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5
... , MORRISVILLE, N.C. , April 23 Asymchem Laboratories ... as Director of Formulation Development, Dr. Pingzhong Huang as Director of Chemical ... Development. , , , ... (George) Xu joined Asymchem on February 1, 2010 .  He ...
... ... Awards Program recognizes these organizations for their outstanding innovations and excellence in the use ... research, and clinical trials. , ... Needham, Mass. (PRWEB) April 23, 2010 -- Bio-IT World magazine announced ...
... ... ISSSEEM conference will be of interest only to those who are going to ... live a life of happiness and value.” The International Society for ... annual conference, Evidence-based Spirituality for the 21st Century, June 25-29, 2010 at the ...
Cached Biology Technology:Asymchem Laboratories Hires Three New Employees: Guojie Xu, Pingzhong Huang, and Xiaojun Huang 2BIO-IT World Announces the Winners of its 2010 Best Practices Awards Program 2BIO-IT World Announces the Winners of its 2010 Best Practices Awards Program 3BIO-IT World Announces the Winners of its 2010 Best Practices Awards Program 4BIO-IT World Announces the Winners of its 2010 Best Practices Awards Program 5BIO-IT World Announces the Winners of its 2010 Best Practices Awards Program 620th Annual ISSSEEM Conference – Evidence-based Spirituality for the 21st Century 220th Annual ISSSEEM Conference – Evidence-based Spirituality for the 21st Century 3
(Date:12/19/2014)... Dec. 18, 2014   LaunchKey , the first ... post-password and Internet of Things era, today announced the ... venture round was led by Metamorphic Ventures with participation ... Partners, VegasTechFund, and others.  LaunchKey has raised $4 million ... expand its team and bring LaunchKey to market in ...
(Date:12/17/2014)... 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend upcoming ... medical sensors in biomedical applications. Chemical sensors help ... correct diagnosis during surgical procedures. The Global Chemical ...
(Date:12/11/2014)... -- That blood pressure plays a role in human health has ... term for high blood pressure – was first described as ... that,s used in measuring blood pressure was invented in 1896. ... hypertension, its triggers and its effects. In fact, recent findings ... best ways to treat it. For example, a ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... Technology and Society Forum presentation on March 23, 2011 ... University Professor Sheena Iyengar, will address the psychological and ... her discipline-spanning research. Her talk, "The ... choice and freedom, and why one doesn,t always complement ...
... WASHINGTON, D.C. (March 8, 2011) -- Researchers at the ... of Texas at Dallas are reporting today at the ... how they are using a novel 3D cell imaging ... transport, providing a solution to this fundamental problem in ...
... blood cell production and function will today be awarded ... Council,s (NHMRC) program grants scheme. The nine ... securing $107 million in program grant funding will be ... the Federal Minister for Mental Health and Ageing, the ...
Cached Biology News:Columbia professor to discuss good, bad aspects of choice at NJIT March 23 talk 2$38.4M NHMRC program grants extend cancer and blood cell research 2
...
Experion spin filters are used to filter the gel matrix and gel stain solution prior to use with the Experion automated electrophoresis system. Supplied as 10 spin filters....
... use in the Microsart e.motion are sterile-sealed, without ... a specially designed individual package on a band. ... of membrane filter units ensures that they are ... sealed band guarantees uniform dispensing of the individual ...
... The model 55S Rocking Shaker provides ... and blotted membranes. The very slow ... degree of tilt provide a gentle ... over gels and blotted membranes to ...
Biology Products: